Regeneration Technologies, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Delayed release of fourth quarter 2001 results will allow evaluation of "certain inventory issues," which could take several weeks, the company discloses Feb. 1. The issues also "may affect RTI's previously reported quarterly financial results," the allograft tissue processing firm cautions. Chief Financial Officer Richard Allen and VP-Sales and Marketing James Abraham have left the company, "effective immediately." Separately, an FDA compliance review of the firm's BioCleanse tissue sterilization process has determined "no regulatory action is warranted" after the agency raised safety concerns last May, according to RTI...